Thank you for your valuable work on vancomycin dosing in hemodialysis patients. I noticed a few areas that could strengthen the paper: (1) the small sample size (20 patients) and single-center scope limit the generalizability of the findings, raising concerns about statistical robustness; (2) the high incidence of supratherapeutic AUCs despite adherence to protocol suggests potential flaws in the dosing strategy or its implementation; and (3) the lack of detailed statistical analysis, such as confidence intervals or hypothesis testing, weakens the validity of the conclusions. Could you address these to enhance the clarity and impact of the study?
